<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11860039</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.686</article-id><article-id pub-id-type="other">EPP0574</article-id><article-id pub-id-type="pii">S0924933824006862</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Comparing IM Lorazepam and IM Clothiapine for Agitated Psychosis in Hospitalized Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kverashvili</surname><given-names>&#x02022;.</given-names></name><xref rid="aff1617" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff1618" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Malik</surname><given-names>E.</given-names></name><xref rid="aff1617" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff1618" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor0547" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Shelef</surname><given-names>&#x02022;.</given-names></name><xref rid="aff1618" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff1619" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Stryjer</surname><given-names>&#x02022;.</given-names></name><xref rid="aff1617" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff1618" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff1617"><sup>1</sup>Psychiatry, <institution>Abarbanel Mental Health Center</institution>, <city>Bat-Yam
</city></aff><aff id="aff1618"><sup>2</sup>Psychiatry, Faculty of Medicine, <institution>Tel-Aviv University</institution>, <city>Tel-Aviv
</city></aff><aff id="aff1619"><sup>3</sup>Psychiatry, <institution>Lev Hasharon Mental Health Center</institution>, <city>Netanya</city>, <country>Israel</country></aff><author-notes><corresp id="cor0547"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="661">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S331</fpage><lpage>S332</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824006862a.pdf"/><abstract><sec id="sec3288"><title>Introduction</title><p>When patients in a closed hospital ward experience acute psychosis and become highly agitated or pose a risk to themselves and others, it&#x02019;s often crucial to provide immediate sedative treatment. However, there is currently no consensus on whether the preferred medication for these situations should be antipsychotic drugs or benzodiazepines.</p></sec><sec id="sec3289"><title>Objectives</title><p>This study aimed to compare how well a single intramuscular dose of 2-4 mg Lorazepam performs against 40 mg Clothiapine in terms of effectiveness and side effects. These treatments were administered as immediate emergency measures to patients experiencing psychosis with severe agitation or behaviors that posed a risk to themselves or their surroundings.</p></sec><sec id="sec3290"><title>Methods</title><p>We conducted a retrospective clinical study involving 100 patients experiencing aggressive psychosis. These patients were divided into two groups. The first group comprised 50 patients who received a single intramuscular (IM) dose of up to 40 mg Clothiapine. The second group consisted of 50 patients who received IM treatment with 2-4 mg Lorazepam. We assessed the patients&#x02019; outcomes around 8 hours after treatment or upon receiving any additional treatment.</p></sec><sec id="sec3291"><title>Results</title><p>There were no significant statistical differences in the demographic and clinical characteristics (e.g., age, gender, number of hospitalizations, duration of illnesses, psychiatric diagnosis, comorbidity) of the patients between the two groups (p &#x0003e; 0.05).</p><p>Before treatment, there were no statistical differences in the severity of clinical symptoms (CGI-S) between the two groups [CGI-S (Mean &#x000b1; SD): 5.32 &#x000b1; 1.09 vs. 5.38 &#x000b1; 1.4, p = 0.8].</p><p>However, in the Clothiapine group, a statistically significant clinical improvement (CGI-I) was observed after treatment [CGI-I (Mean &#x000b1; SD): 2.42 &#x000b1; 0.9 vs. 1.96 &#x000b1; 1.16, p = 0.029 *].</p><p>There were no significant differences in the need for physical restraint or additional medication following the initial treatment between the two groups (p &#x0003e; 0.05).</p><p>Furthermore, there were no statistically significant differences in the major side effects of the drugs, the necessity for referral to the general emergency room, or incidents of falls (p &#x0003e; 0.05).</p></sec><sec id="sec3292"><title>Conclusions</title><p>When dealing with a psychotic state marked by severe agitation or threats to oneself and others, the use of IM Clothiapine as a treatment option may offer certain advantages over IM Lorazepam. Importantly, these advantages come without significant exposure to side effects or potential risks associated with Clothiapine.</p></sec><sec id="sec3293"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>